BOSTON--(BUSINESS WIRE)--Emulate, Inc. today announced that the company has completed the 150th installation of its Zoë® instrument, part of a lab-ready platform for Organs-on-Chips technology for use by researchers across many industries, particularly with early adopters conducting R&D related to drug discovery and development. Emulate has expanded its portfolio of commercially available Zoë-compatible chips to now include the Liver-Chip, Kidney-Chip, and Intestine-Chip. Each Organ-Chip features tiny channels lined with tens of thousands of living human cells, re-creating the natural physiology and enabling true-to-life biology outside of the body.
The 150 installations include customers in 10 of the top 25 global biopharmaceutical companies, as well as leading international academic research centers and U.S. government laboratories, including the U.S. FDA through a collaborative agreement and the U.S. Army. Organs-on-Chips technology enables researchers to predict human responses in the lab to answer the complex questions required for disease modeling, target validation, and drug development, ranging from safety and efficacy of drug candidates to new understanding of disease mechanisms. Emulate's ongoing R&D is supporting the development of additional Organ-Chips, such as the Brain-Chip, and new applications in key areas of biology and diseases, including applications in neurodegenerative disease, gastrointestinal diseases, and infectious diseases, such as COVID-19.
“We’re pleased to reach this milestone for the adoption of our products by leaders in the drug development ecosystem, putting Organs-on-Chips technology in the hands of researchers worldwide. Researchers in industry, government, and academia are using our Zoë lab-ready instrument and our Organs-on-Chips for a range of applications including human-relevant disease modeling and studies to gain new insights into disease mechanisms that will enable novel therapeutics development. We are excited to see our customers and users produce groundbreaking research from our platform, adding new human-relevant data to conventional areas of testing, such as safety studies, as well as generating entirely new findings related to new drug modalities and disease mechanisms that are not feasible with conventional animal models or cell cultures,” said Geraldine A. Hamilton, President and Chief Scientific Officer of Emulate. “We are actively working on the development of new applications to expand our product portfolio so that, through the use of our platform, our community of users can help improve human health and bring new and better cures to patients.”
Emulate's platform integrates into the workflows of researchers developing new drugs and products, enabling them to conduct complex experiments with no prior experience with Organs-on-Chips technology. The platform provides human-relevant mechanistic data on toxicity and diseases that researchers can use to assess safety risks and make informed, efficient decisions throughout the drug discovery and development process . In addition to the applications in drug development, Emulate’s platform can be used in other industries, including cosmetics, food, chemical-based consumer products, and personalized health, to enable new understanding of human responses to drugs, chemicals, food, and diseases.
Emulate’s platform is comprised of the following key components:
- Organ-Chips that have a proprietary design to support dynamic cellular interactions, including tissue-to-tissue interfaces, media flow, and mechanical forces that emulate the appropriate microenvironment cells need for accurate biological translation.
- Zoë® Culture Module is a lab-ready instrument that automates the dynamic flow of cell culture media and the mechanical forces required for any user to work with Organ-Chips in a robust and reproducible manner. Zoë instrumentation can run up to 12 Organ-Chips simultaneously and is powered by the Orb™ Hub Module, which provides the precise required mixture of gas, power, and vacuum stretch.
User application tools, including content and software:
- Experimental applications content that provides users with protocols, study plans, and representative data sets for specific applications of the platform such as Liver Mechanistic Toxicity, Kidney Drug Transport, and Intestine Absorption and Metabolism.
- Software applications that enable study design and management, data analysis, integration with standard analytical tools, and collaboration among teams using Emulate’s platform.
Information about Emulate’s products are available on the Products section of the company’s website.
About Emulate, Inc.
Emulate Inc. is a privately held company that creates living products for understanding how diseases, medicines, chemicals, and foods affect human health. Our lab-ready platform, including Zoë® instrumentation, Organ-Chips, and application tools, provides a window into the inner workings of human biology and disease — offering researchers a new technology designed to predict human response with greater precision and detail than conventional cell culture or animal-based experimental testing. Each of Emulate’s proprietary Organ-Chips — including the liver, intestine and kidney — contains tiny hollow channels lined with tens of thousands of living human cells and tissues and are approximately the size of an AA battery. An Organ-Chip is a living, microengineered environment that recreates the natural physiology and mechanical forces that cells experience within the human body. Our founding team pioneered the Organs-on-Chips technology at the Wyss Institute for Biologically Inspired Engineering at Harvard University. Emulate holds the worldwide exclusive license from Harvard University to a robust and broad intellectual property portfolio for the Organs-on-Chips technology and related systems. For more information, please visit www.emulatebio.com.